FINWIRES · TerminalLIVE
FINWIRES

Ericsson Faces Slower Telecom Spending, Margin Pressure, Morgan Stanley Says

By

Ericsson's (ERIC) revenue growth and profit margins may weaken as telecommunications operators remain "conservative" on network spending and component costs rise, Morgan Stanley said Tuesday in a report.

Morgan Stanley cut its 2027 operating profit estimate by 5% and its outlook for earnings per share by 6% on margin concerns. It downgraded Ericsson to underweight from equal weight and cut its price target on the American depositary receipts to $9 from $11.

The mobile radio access network market is expected to remain "flat going into 2027," the report said. Ericsson's network revenue in the profitable North America region fell 5% in Q2 from a year earlier "after several years of strong growth," Morgan Stanley said.

Ericsson forecast Q3 networks gross margins of 48% to 50%, down about 100 basis points from Q2 as some projects move into lower-margin rollout phases, the report said. Higher semiconductor costs may add further pressure in 2027, Morgan Stanley said.

Price: $9.81, Change: $-0.44, Percent Change: -4.29%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA